Target Testosterone Level for Supplementation in Males
When initiating testosterone supplementation in adult males with hypogonadism, aim to maintain serum testosterone concentrations in the mid-normal range for healthy young men, specifically between 450-600 ng/dL (15.6-20.8 nmol/L). 1
Therapeutic Target Range
The Endocrine Society Clinical Practice Guideline explicitly recommends maintaining testosterone levels in the mid-normal range during treatment 1. Recent evidence from 2025 further specifies this target as 450-600 ng/dL 2. This range represents the middle portion of the normal reference range for healthy young adult males and provides optimal symptom relief while minimizing adverse effects.
Formulation-Specific Monitoring Targets
The target range applies across formulations, but timing of measurement varies:
Injectable testosterone (enanthate/cypionate): Measure mid-interval between injections. Adjust if levels are >600 ng/dL (24.5 nmol/L) or <350 ng/dL (14.1 nmol/L) 1
Transdermal gels: Assess 2-8 hours after application, after at least 1 week of treatment. Adjust dose to achieve mid-normal range 1
Transdermal patches: Measure 3-12 hours after application 1
Monitoring Timeline
Check testosterone levels at 3-6 months after initiation (timing depends on formulation), then at 12 months, and annually thereafter 1. This allows adequate time for steady-state levels to be achieved and ensures sustained therapeutic benefit.
Critical Context: Diagnosis Before Treatment
Before targeting any testosterone level with supplementation, confirm the diagnosis requires:
- Two separate fasting morning testosterone measurements showing total testosterone <300-350 ng/dL (10.4-12.1 nmol/L) 3, 2, 4
- Presence of hypogonadal symptoms (sexual dysfunction, fatigue, mood changes, reduced muscle mass) 1, 2
- Exclusion of organic causes of hypogonadism through LH/FSH measurement 5
The European Association of Urology 2025 guidelines set the diagnostic threshold at <12 nmol/L (346 ng/dL) confirmed by two morning samples 5.
Safety Boundaries
Avoid supraphysiologic levels. Testosterone concentrations consistently >600 ng/dL increase risks of:
- Erythrocytosis (hematocrit >48-50% is a relative contraindication for continued therapy) 6
- Potential cardiovascular effects (mild systolic blood pressure elevation documented in TRAVERSE trial) 5
Avoid subtherapeutic dosing. Levels persistently <350 ng/dL indicate inadequate replacement and require dose adjustment 1.
Common Pitfall
Many clinicians target the lower end of normal or accept levels just above the diagnostic threshold. This approach leaves patients symptomatic. The evidence clearly supports targeting the middle of the normal range, not merely "above low" 1, 2. The mid-normal target (450-600 ng/dL) has demonstrated improvements in sexual function, body composition, metabolic profile, and bone density without increasing major cardiovascular events or prostate cancer risk 2.